Abstracts tagged "glucocorticoids"

Abstract Number: 554 • 2019 ACR/ARP Annual Meeting
Evidence to Guide Glucocorticoid Tapering Is Lacking in RA
Beth Wallace¹, David Wallace ², Akbar Waljee ³ and Daniel Clauw ⁴, ¹Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Division of General Medicine, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ³Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Over a third of RA patients are managed with long-term oral glucocorticoids (GC), defined as daily GC use for ≥3 months[1]. Due to dose-dependent…
Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Qufei Wu ², Lang Chen ⁴, Fenglong Xie ⁵, Huifeng Yun ⁴ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
JB Boone¹, S. Bobo Tanner ¹ and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…
Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Shintaro Hirata¹, Takuji Omoto ¹, Hiroki Kohno ¹, Hirofumi Watanabe ¹, Kazutoshi Yukawa ¹, Tadahiro Tokunaga ¹, Tatsuomi Kuranobu ¹, Katsuhiro Oi ¹, Yusuke Yoshida ¹, Tomohiro Sugimoto ¹, Sho Mokuda ¹, Keisuke Oda ¹, Takaki Nojima ¹ and Eiji Sugiyama ¹, ¹Hiroshima University, Hiroshima, Japan
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…
Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…
Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Dieter Goette¹ and Peter Rutherford ¹, ¹Vifor Pharma, Zurich, Zurich, Switzerland
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…
Abstract Number: 1876 • 2019 ACR/ARP Annual Meeting
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Kenneth Saag¹, Michele McDermott ², Jonathan Adachi ³, Willem Lems ⁴, Nancy Lane ⁵, Piet Geusens ⁶, Peter Butler ², Li Chen ², Daria Crittenden ², Robin Dore ⁷ and Stanley Cohen ⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴VU University Medical Centre, Amsterdam, Netherlands, ⁵University of California at Davis Medical Center, Sacramento, CA, ⁶Maastricht University, Maastricht, Netherlands, ⁷Robin K Dore Inc, Tustin, CA, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Denosumab, a monoclonal antibody against RANKL, is approved for the treatment of glucocorticoid (GC) induced osteoporosis (GiOP). In postmenopausal women with osteoporosis, denosumab discontinuation…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 2675 • 2019 ACR/ARP Annual Meeting
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
Jennie Best¹, Amanda M. Kong ², Oth Tran ² and Margaret Michalska ¹, ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Cambridge, MA
Background/Purpose: Oral glucocorticoids (OGC) have been the mainstay of treatment for giant cell arteritis (GCA). However, OGCs are associated with several adverse events (AEs). The…
Abstract Number: 2691 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Gary Craig¹, Keith Knapp ², Bob Salim ³, Shalini Mohan ⁴ and Margaret Michalska ⁴, ¹Arthritis Northwest; Discus Analytics, Spokane, WA, ²Discus Analytics, Spokane, WA, ³Axio Research, Seattle, WA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: For patients with giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR), glucocorticoids are the mainstay of treatment. However, due to the chronic nature of…
Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Gerd R. Burmester¹, Frank Buttgereit¹, Corrado Bernasconi², Jose Maria Alvaro-Gracia³, Nidia Castro², Maxime Dougados⁴, Cem Gabay⁵, Jacob van Laar⁶, J. Michael Nebesky², Attila Pethö-Schramm², Carlo Salvarani⁷, Marc Y. Donath⁸ and Markus R. John², ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, ⁴Université Paris-Descartes, Paris, France, ⁵University Hospitals of Geneva, Geneva, Switzerland, ⁶University Medical Centre Utrecht, Utrecht, Netherlands, ⁷Università de Modena e Reggio Emilia, Modena, Italy, ⁸University Hospital Basel, Basel, Switzerland
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
Abstract Number: 2340 • 2018 ACR/ARHP Annual Meeting
The Impact of Chronic Glucocorticoid Use Amongst Patients with Rheumatoid Arthritis: A Qualitative Study
Jonathan Cheah^1,2, Sarah Young³, Susan M. Goodman^4,5, Catherine Hill^6,7, Susan Beard⁸, Pamela Richards⁹, Sarah Mackie¹⁰, Joanna Robson^11,12 and Iris Navarro-Millán^5,13, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Medicine, Weill Cornell Medicine, New York, NY, ³Binghamton University, Binghamton, NY, ⁴Rheumatology, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶The Queen Elizabeth Hospital, Adelaide, Australia, ⁷Medicine, The University of Adelaide, Adelaide, Australia, ⁸Patient Research Partner, Adelaide, Australia, ⁹Patient Research Partner, Bristol, United Kingdom, ¹⁰NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ¹¹Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom, ¹²School of Clinical Sciences, University of Bristol, Bristol, United Kingdom, ¹³Weill Cornell Medicine, New York, NY
Background/Purpose: Glucocorticoids (GCs) have well documented adverse effects. However, the absolute risk and importance of these effects have not been well documented from the perspective…
Abstract Number: 534 • 2018 ACR/ARHP Annual Meeting
Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy?
Gorica Ristic¹, Vesna Subota², Dejana Stanisavljevic³, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Increased insulin resistance and impaired β-cell function have been demonstrated in rheumatoid arthritis (RA). The aim of the study was to analyze the association…
Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
Abstract Number: 545 • 2018 ACR/ARHP Annual Meeting
How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry
Sytske Anne Bergstra¹, Lai-Ling Winchow², Elizabeth Murphy³, Arvind Chopra⁴, Karen Salomon-Escoto⁵, João E. Fonseca⁶, Cornelia F. Allaart¹ and Robert B.M. Landewé⁷, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²University of the Witwatersrand, Johannesburg, South Africa, ³University Hospital Wishaw, Scotland, Wishaw, United Kingdom, ⁴Center for Rheumatic Diseases, Pune, India, ⁵University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, ⁶Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Amsterdam Rheumatology & Immunology Center | Zuyderland Medical Center, Heerlen, Netherlands
Background/Purpose: After failure of initial methotrexate (MTX) treatment in rheumatoid arthritis (RA) patients, various treatment options can be considered. To date, evidence about the preferred…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].